Skip to main content
logo
Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.775
+0.105 (2.86%)
At close: Oct 5, 2026, 4:00 PM EDT
3.770
-0.005 (-0.13%)
After-hours: Oct 5, 2026, 4:10 PM EDT

Prelude Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
22.4212.147---
Revenue Growth
220.34%73.43%----
Gross Profit
22.4212.147---
Operating Income
-66.1-103.27-139.71-132.28-123.54-113.74
Net Income
-60.49-99.5-127.17-121.83-115.44-111.69
Earnings Per Share
-0.72-1.29-1.68-2.02-2.44-2.43
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
151.76103.21133.61232.94201.73291.23
Total Debt
17.6517.7918.0316.891.831.74
Net Cash (Debt)
134.1185.43115.59216.05199.9289.49
Net Cash Growth
142.51%-26.10%-46.50%8.08%-30.95%32.61%
Net Cash Per Share
1.591.111.523.584.226.29

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-33.26-56.3-102.89-107.06-83.73-83.53
Capital Expenditures
--0.07-0.76-3.51-3.02-2.32
Free Cash Flow
-33.26-56.37-103.65-110.58-86.75-85.85
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-294.76%-850.63%-1995.91%---
Pretax Margin
-269.75%-819.59%-1816.76%---
Profit Margin
-269.75%-819.59%-1816.76%---
FCF Margin
-148.30%-464.32%-1480.74%---

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
17.3219.6813.82---